Michael Kalos

3 ta ish

University of Pennsylvania

1. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

   Stephan A. Grupp, Michael Kalos, David M. Barrett +10

   MaqolaOAOchiq kirish20133 iqtibos

   ABIABI:AkademIndex/2026.other.082765

2. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

   Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9

   MaqolaOAOchiq kirish20132 iqtibos

   ABIABI:AkademIndex/2026.other.082777

3. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

   Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons +35

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.475807